NASDAQ · SYRE
Spyre Therapeutics, Inc.
$96.06-$2.90 (-2.93%)
Spyre Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.85% below the high.
Loading market information…
NASDAQ · MGTA · USD
Stock price, earnings
Quote as of Sep 11, 2023, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Magenta Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.35% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Magenta Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Magenta Therapeutics, Inc. is a biotechnology firm in the clinical development stage, dedicated to advancing therapies that leverage the transformative potential of stem cell transplantation for individuals afflicted with blood cancers, genetic illnesses, and autoimmune conditions. Among its key pipeline candidates is MGTA-117, an anti-CD117 antibody. This compound specifically targets hematopoietic stem cells (HSCs) and the genetically altered stem cells implicated in acute myeloid leukemia and myelodysplastic syndromes, and is currently progressing through Phase I/II clinical trials. Additionally, the company is developing a CD45-antibody drug conjugate, designed to target both HSCs and immune cells. This asset is in investigational new drug (IND) enabling studies, exploring its potential as a monotherapy for autoimmune diseases and in hematology-oncology transplant settings. Another therapeutic, MGTA-145, is undergoing Phase II clinical evaluation for its application in both autologous and allogeneic transplant procedures. Beyond these, Magenta boasts a cell therapy initiative featuring E478, a small molecule aryl hydrocarbon receptor antagonist, which is being explored for stem cell-based gene therapy and genome editing. The company actively engages in strategic alliances, including a research and clinical collaboration with AVROBIO, Inc. focused on treating lysosomal storage disorders. Furthermore, it partners with Beam Therapeutics, Inc. to investigate the utility of MGTA-117 as a conditioning regimen for patients with sickle cell disease and beta-thalassemia. Originally incorporated in 2015 as HSCTCo Therapeutics, Inc., the company adopted its current name, Magenta Therapeutics, Inc., in February 2016. Its corporate headquarters are situated in Cambridge, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:20 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2021 |
|---|
| Mar 8, 2022 |
| $0.33+3.13% vs estimate |
| $0.00 |
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$96.06-$2.90 (-2.93%)
Spyre Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.85% below the high.
$0.68-$0.04 (-5.84%)
Rein Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.61% below the high.
$9.81+$0.39 (+4.14%)
AlloVir, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.38% below the high.
$4.97$0.00 (0.0%)
bluebird bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.62% below the high.
$0.30-$0.00 (-0.03%)
GreenLight Biosciences Holdings’s quoted price sits in the lower half of its reported 52-week range, 94.92% below the high.
$1.00-$0.03 (-2.91%)
Pluristem Therapeutics Inc.: Healthcare · Biotechnology.
$7.56+$0.29 (+3.99%)
Eyenovia, Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.94% below the high.
$4.34$0.00 (0.0%)
Lumos Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.15% below the high.
